Omentin-1 Level in Psoriatic Patients Treated With Narrowband Ultraviolet B Phototherapy Versus Acitretin

NCT ID: NCT05203354

Last Updated: 2022-01-24

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-09-01

Study Completion Date

2021-08-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Studying the effects of Narrowband Ultraviolet B versus acitretin on psoriatic patients

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Compare the effects of Narrowband Ultraviolet B versus acitretin on serum Omentin-1 level in psoriatic patients as case control study by dividing patients into 3 groups: group 1 include patients receive Narrowband Ultraviolet B, group II includes patients receive acitretin (0.5-1 mg/day) and control group. The duration of this study about 3 months after receving those interventions.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Psoriasis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

NB-UVB group

Patients who receive Narrowband ultraviolet B phototherapy

Group Type ACTIVE_COMPARATOR

Narrowband Ultraviolet B

Intervention Type RADIATION

patients will exposed to sessions of NB-UVB phototherapy twice weekly for 3 months

Acitretin group

Patients who receive acitretin

Group Type ACTIVE_COMPARATOR

Acitretin

Intervention Type DRUG

patients will received acitretin in dose 0.5-1 mg/kg daily for 3 months

Control group

It includes apparently healthy people who will be compared to patients in the measurement of Omentin-1 level

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Narrowband Ultraviolet B

patients will exposed to sessions of NB-UVB phototherapy twice weekly for 3 months

Intervention Type RADIATION

Acitretin

patients will received acitretin in dose 0.5-1 mg/kg daily for 3 months

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

NB-UVB phototherapy

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients of both sexes with psoriasis vulgaris.

Exclusion Criteria

* • Patients with history of malignancies, renal and liver diseases.

* Patients received NB-UVB phototherapy in the last 6 months.
* Patients treated with methotrexate or biologic agents and any systemic treatment of psoriasis.
Minimum Eligible Age

20 Years

Maximum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Mahmoud Ahmed Ali Ahmed

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Mahmoud Ahmed Ali Ahmed

Assistant lecturer

Responsibility Role SPONSOR_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Faculty of medicine - Aswan university

Aswān, , Egypt

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Egypt

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

288/9/18

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Excimer Light in Psoriasis
NCT05283876 COMPLETED NA